Eindhoven-based Microsure, a medtech company specialising in robot-assisted micro-surgery, has grabbed €38 million in a Series B2 funding round.
Stellar list of investors
The investment came from a host of new investors, including the European Innovation Council Fund (EICF), kineo (that backed Kiwibot and Storebox), Invest-NL that recently backed Extantia Capital, and several prominent private investor groups.
Also, Microsure has acknowledged the support of key existing shareholders, including deep-tech venture capital firm Innovation Industries, BOM Ventures, private investors Ten Cate Investerings Maatschappij (TCIM), Venturing Tech, Eindhoven University of Technology (TU/e), and Microsure Founders.
The company has been recognised with an EIC Accelerator grant, and an Innovation Loan from RvO, a division of the Dutch Ministry of Economic Affairs. It has entered into an asset financing agreement with kineo, enabling Microsure to offer appealing leasing options to hospitals adopting MUSA-3, Microsure’s first commercial product.
With this funding, Microsure will finalise the development of its newest microsurgical robot MUSA-3 (picture) for clinical studies followed by FDA clearance in the USA and CE-mark in Europe.
As part of this financing round, Kreske Nickelsen from new investor kineo will join the supervisory board, further strengthening Microsure’s governance.
Prominent microsurgery expert Professor Peter Neligan, author of the standard handbook on Plastic Surgery (5th edition, Elsevier, 2023) stated, “Microsure’s pioneering innovations in the realm of microsurgery represent a transformative leap for our field. Their unwavering commitment to precision and their groundbreaking technologies have opened new horizons for microsurgical techniques. As someone deeply involved in advancing the frontiers of microsurgery, I wholeheartedly commend Microsure’s remarkable contributions, which are instrumental in redefining our approach to complex procedures and significantly improve patient outcomes.”
Svetoslava Georgieva, Chair of the EIC Fund Board, said, “We are glad to support Microsure through this investment round. We believe they can make a significant difference in the lives of patients in need of microsurgery. With the current funding round, we are confident that Microsure’s team will be able to successfully introduce MUSA-3 to the EU markets.“
Sjaak Deckers, CEO of Microsure, emphatically stated, “We extend our deep gratitude to both our new and steadfast existing investors for their unwavering support, which has propelled Microsure to new heights. The financing will enable us to advance our groundbreaking technology and bring innovative solutions to patients worldwide through our MUSA-3 robotic system.”
MUSA-3: A microsurgical robot
Microsure was founded in 2016 by Raimondo Cau and Tom Van Mulken. Its microsurgical robot MUSA-3 is designed to revolutionise the field of open microsurgery, helping microsurgeons to excel and leave no patient untreated. It represents a giant leap in microsurgical technology, poised to empower surgeons with unprecedented precision, stability and control beyond human capabilities, elevating patient care to new heights in the future of microsurgery.
Building on the success of MUSA-2, MUSA-3 is touted to offer tremor reduction for enhanced precision and seamless integration with surgeons’ existing preferred micro-instruments of different well-known top brands. Its adaptability is claimed to allow it to be used in a wide range of surgical procedures.
MUSA-3 combines surgeon comfort with improved ergonomics, enabling surgeons to work from a surgeon console with digital exoscopes or hybrid surgical microscopes.
